OT mobile menu

Search form



Combination Therapy Active in Children, AYAs With Hodgkin Lymphoma

Brentuximab vedotin combined with gemcitabine may be a new treatment option for children and AYA patients with Hodgkin lymphoma.

Image © tomorn pukesorn/shutterstock.com

Recent Content

The Right to Try Act, if signed by the President, will give terminal cancer patients access to experimental drugs, especially when other treatment options have been exhausted.

Osimertinib demonstrated clinically meaningful progression-free survival benefit in EGFR mutation–positive NSCLC compared with current standard of care.

A recent analysis of 360 primary breast cancer genomes has identified some potentially important cancer-driving mutations found within noncoding genomic regions.

A new study indicates that patients with primary immunodeficiency diseases may be at a much higher risk for certain cancers, especially lymphoma.

Researchers in Spain discovered a strange side effect of PD-L1 immunotherapy in some NSCLC patients—hair repigmentation—that may be a good response marker for this treatment.

In this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.

Comprehensive sequencing for all breast cancer genes may provide complete relevant genetic information for Ashkenazi Jewish patients.

By clicking Accept, you agree to become a member of the UBM Medica Community.